Skip to content
value.today

Linnaeus Therapeutics, Inc.

🇺🇸 Haddonfield, New Jersey, USABiotechnologyFounded 2015
Total raised
$26 M
7 rounds on record
Latest round
$4 M
Nov 2026
First round on record
Aug 2018
Today
Private
No later event on record

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Linnaeus Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2026$4 MNo. 7$2 to $10 million

Linnaeus Therapeutics, Inc.: Raise no. 7, Nov 2026

Investors in this round

4 investors had bought by the notice of Nov 18, 2026: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $10 M offered; $6 M still to sell
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Chris Arendt · Director
  • James 30 Washington Avenue, Suite F · Director
  • John Lepping · Director
  • Michael Poisel · Director
  • Patrick Mooney · Director
  • Todd Thomson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Anthony Gruzdis, Attorney-in-fact. Source: SEC Form D, newest notice filed Nov 18, 2026. Read the notice at the SEC.

equitySEC
Feb 2026$5 MNo. 6$2 to $10 million

Linnaeus Therapeutics, Inc.: Raise no. 6, Feb 2026

Investors in this round

26 investors had bought by the notice of Apr 2, 2026: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $10 M offered; $5 M still to sell
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Patrick Mooney · Executive Officer, Director
  • Chris Arendt · Director
  • James Demetriades · Director
  • John Lepping · Director
  • Michael Poisel · Director
  • Todd Thomson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Anthony Gruzdis, Attorney-in-fact. Source: SEC Form D and 3 amendments, newest notice filed Apr 2, 2026. Read the notice at the SEC.

equitySEC
Aug 2024$6 MNo. 5$2 to $10 million

Linnaeus Therapeutics, Inc.: Raise no. 5, Aug 2024

Investors in this round

12 investors had bought by the notice of Dec 26, 2024: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $7 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
  • Section 4(a)(5): accredited investors only, up to $5 million, no public advertising
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Patrick T. Mooney · Executive Officer
  • Chris D. Arendt · Director
  • James T. Demetriades · Director
  • Michael D. Poisel · Director
  • Todd T. Thomson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mariel J. Giletto, Attorney-in-fact. Source: SEC Form D and 1 amendment, newest notice filed Dec 26, 2024. Read the notice at the SEC.

equitySEC
Jan 2023$3 MNo. 4$2 to $10 million

Linnaeus Therapeutics, Inc.: Raise no. 4, Jan 2023

Investors in this round

8 investors had bought by the notice of Jan 26, 2023: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$15,700
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
  • Section 4(a)(5): accredited investors only, up to $5 million, no public advertising
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Patrick T. Mooney · Executive Officer, Director
  • Michael D. Poisel · Director
  • Nicholas T. Iatropoulos · Director
  • Todd T. Thomson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mariel J. Giletto, Attorney-in-fact. Source: SEC Form D, newest notice filed Jan 26, 2023. Read the notice at the SEC.

equitySEC
Aug 2021$4 MNo. 3$2 to $10 million

Linnaeus Therapeutics, Inc.: Raise no. 3, Aug 2021

Investors in this round

15 investors had bought by the notice of Aug 24, 2021: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
$24,999
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
  • Section 4(a)(5): accredited investors only, up to $5 million, no public advertising
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Patrick T. Mooney · Executive Officer, Director
  • Michael D. Poisel · Director
  • Nicholas T. Iatropoulos · Director
  • Todd T. Thomson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mariel J. Giletto, Attorney-in-fact. Source: SEC Form D, newest notice filed Aug 24, 2021. Read the notice at the SEC.

equitySEC
Jan 2019$2 MNo. 2$2 to $10 million

Linnaeus Therapeutics, Inc.: Raise no. 2, Jan 2019

Investors in this round

3 investors had bought by the notice of Feb 8, 2019: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
  • Section 4(a)(5): accredited investors only, up to $5 million, no public advertising
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$28,919 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher D. Natale · Executive Officer
  • Patrick T. Mooney · Executive Officer, Director
  • Michael D. Poisel · Director
  • Nicholas D. Iatropoulos · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Approximately $28,919 of the proceeds may be used to repay the remaining principal of a promissory note made to the issuer by the issuer's CEO. The decision to repay the principal will be at the discretion of the issuer's board of directors.”

Signed by Adam Chelminiak, Attorney-in-fact. Source: SEC Form D, newest notice filed Feb 8, 2019. Read the notice at the SEC.

equitySEC
Aug 2018$2 MNo. 1$2 to $10 million

Linnaeus Therapeutics, Inc.: Raise no. 1, Aug 2018

Investors in this round

4 investors had bought by the notice of Sep 7, 2018: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
  • Section 4(a)(5): accredited investors only, up to $5 million, no public advertising
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$100,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher D. Natale · Executive Officer
  • Patrick T. Mooney · Executive Officer, Director
  • Michael D. Poisel · Director
  • Nicholas D. Iatropoulos · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “A second tranche of $2,160,000 will be sold within the next 9 months if the issuer achieves certain milestone events.”
  • On the use of proceeds: “Approximately $100,000 of the proceeds of this offering may be used to repay the principal of a promissory note made to the issuer by the issuer's CEO. The decision to repay the principal will be at the discretion of the issuer's board of directors.”

Signed by Adam Chelminiak, Attorney-in-fact. Source: SEC Form D, newest notice filed Sep 7, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Linnaeus Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2026).

    SEC Form D · Nov 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2026

That is all the official record says: Linnaeus Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Linnaeus Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 26 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Linnaeus Therapeutics, Inc.
NameRoleNamed in
Patrick MooneyExecutive officerApr 2026
Patrick T. MooneyExecutive officerDec 2024
Christopher D. NataleExecutive officerFeb 2019
Chris ArendtDirectorNov 2026
James 30 Washington Avenue, Suite FDirectorNov 2026
John LeppingDirectorNov 2026
Michael PoiselDirectorNov 2026
Patrick MooneyDirectorNov 2026
Todd ThomsonDirectorNov 2026
James DemetriadesDirectorApr 2026
Chris D. ArendtDirectorDec 2024
James T. DemetriadesDirectorDec 2024
Michael D. PoiselDirectorDec 2024
Todd T. ThomsonDirectorDec 2024
Nicholas T. IatropoulosDirectorJan 2023
Patrick T. MooneyDirectorJan 2023
Nicholas D. IatropoulosDirectorFeb 2019